使用警語:中文譯文來源為 AI 翻譯,僅供參考,實際內容請以英文原文為主
Operator
Operator
Good morning, and welcome to the Bausch Health Care Fourth Quarter 2018 Earnings Conference Call. (Operator Instructions) Please note, today's event is being recorded.
早安,歡迎參加 Bausch Health Care 2018 年第四季財報電話會議。(接線員指示) 請注意,今天的活動將被錄音。
I would now like to turn the conference over to Art Shannon, Senior Vice President of Investor Relations and Communications. Please go ahead, sir.
現在我想把會議交給投資人關係與傳播資深副總裁 Art Shannon。先生,請開始。
Arthur J. Shannon - Senior VP and Head of IR & Communications
Arthur J. Shannon - Senior VP and Head of IR & Communications
Thank you, Rocco. Good morning, everyone, and welcome to our Fourth Quarter and Full Year 2018 Financial Results Conference Call. Participating on today's call are Chairman and Chief Executive Officer, Mr. Joe Papa; and Chief Financial Officer, Mr. Paul Herendeen. In addition to this live webcast, a copy of today's slide presentation and a replay of this conference call will be available on our website under the Investor Relations section.
謝謝你,Rocco。各位早安,歡迎參加我們 2018 年第四季及全年財務結果電話會議。今天參與電話會議的有董事長兼執行長 Joe Papa 先生,以及財務長 Paul Herendeen 先生。除本次即時網路直播外,今日簡報投影片的副本以及本次電話會議的重播,將可於我們網站「投資人關係」專區取得。
Before we begin, we'd like to remind you that our presentation today contains forward-looking information. We would ask that you take a moment to read the forward-looking statement legend at the beginning of our presentation as it contains important information. This presentation contains non-GAAP financial measures. For more information about these measures, please refer to Slide 2 of the presentation. Non-GAAP reconciliations can be found in the appendix of the presentation posted on our website.
在開始之前,我們想提醒各位,今天的簡報包含前瞻性資訊。請各位花點時間閱讀簡報開頭的前瞻性聲明說明,因其包含重要資訊。本簡報包含非 GAAP 財務衡量指標。關於這些指標的更多資訊,請參閱簡報第 2 頁。非 GAAP 調節表可在我們網站所發布簡報的附錄中找到。
Finally, the financial guidance in this presentation is effective as of today only. It is our policy to generally not update guidance until the following quarter and not to update or affirm guidance other than through broadly disseminated public disclosure. And with that, it is my pleasure to turn the call over to Joe.
最後,本簡報中的財務指引僅以今日為準。我們的政策通常是在下一季之前不更新指引,且除透過廣泛公開揭露外,不更新或確認指引。那麼,我很高興把電話會議交給 Joe。
Joseph C. Papa - CEO & Chairman of the Board
Joseph C. Papa - CEO & Chairman of the Board
Thank you, Art, and thanks, everyone on the phone for joining us today. Let's quickly review the topics we will cover. I'll begin with a brief summary of our 2018 company highlights before turning the call over to Paul Herendeen, our CFO. Paul will take us through the fourth quarter and the full year financial results and provide our 2019 guidance.
謝謝你,Art,也感謝各位在電話線上今天加入我們。讓我們快速回顧今天將涵蓋的主題。我將先簡要總結我們 2018 年的公司亮點,接著把電話會議交給我們的財務長 Paul Herendeen。Paul 將帶領我們檢視第四季與全年財務結果,並提供 2019 年指引。
I will then review the segment highlights and catalyst before opening the line for questions. Beginning on Slide 4. 2018 was a year of strong execution for Bausch Health. For the full year, the total company grew organically by 2%. This was the first year of total company organic revenue growth since 2015.
接著我將回顧各事業部亮點與催化因素,然後開放提問。從第 4 頁投影片開始。2018 年對 Bausch Health 而言是執行力強勁的一年。全年而言,公司整體有機成長 2%。這是自 2015 年以來,公司整體首次出現有機營收成長。
We also generated organic revenue growth in all 4 quarters of 2018. B + L/International and Salix, our 2 largest segments, grew organically by 6% on a combined basis during 2018.
我們也在 2018 年四個季度皆達成有機營收成長。B + L/International 與 Salix 這兩個最大事業部在 2018 年合計有機成長 6%。
Our top 10 products grew organically by 11% in the aggregate compared to 2017. We generated $1.5 billion of cash from operations. We increased R&D investment by more than 30% in the fourth quarter and approximately 15% for the full year. And we improved our gross margin through manufacturing efficiencies both in the fourth quarter and the full year.
我們前 10 大產品合計相較 2017 年有機成長 11%。我們創造了 15 億美元的營運現金流。我們在第四季將研發投資提高超過 30%,全年約提高 15%。我們透過製造效率提升,在第四季與全年皆改善了毛利率。
And we resolved the XIFAXAN IP litigation, which we believe preserves the products' market exclusivity until 2028.
此外,我們解決了 XIFAXAN 的智慧財產權訴訟,我們相信這可維持該產品的市場獨占性至 2028 年。
Moving to the top right, we launched 10 key products during 2018, including 2 co-promotions. 4 of our Significant Seven products were launched during the year, and we are expecting a decision from the FDA on DUOBRII shortly.
看右上角,我們在 2018 年推出 10 項關鍵產品,其中包含 2 項共同推廣。我們「重要七項」產品中有 4 項於今年上市,且我們預期 FDA 將很快就 DUOBRII 做出決定。
We'll also continue to delever our balance sheet, having repaid more than $1 billion of debt in 2018 and cash generated from operations.
我們也將持續降低資產負債表槓桿;2018 年我們已償還超過 10 億美元的債務,並運用營運所產生的現金。
Finally, in 2018, we refinanced approximately $8.3 billion of debt to extend maturities and provide more flexibility, which gives us the ability to pivot to offense in 2019.
最後,在 2018 年,我們為約 83 億美元的債務進行再融資,以延長到期日並提供更大的彈性,這使我們能在 2019 年轉為更積極的進攻策略。
Turning to Slide 5. We have a snapshot of the key 2018 financial highlights for each of the 4 segments. Approximately 75% of our total 2018 revenue was generated by the B + L/International segment and the Salix segment combined. B + L/International grew organically by 4% compared to 2017 with organic growth across all 5 reporting businesses.
接著看第 5 頁投影片。我們提供四個事業部在 2018 年的主要財務亮點快照。我們 2018 年總營收約 75% 由 B + L/International 事業部與 Salix 事業部合計貢獻。B + L/International 相較 2017 年有機成長 4%,且五個申報業務皆呈現有機成長。
Salix grew by 12% organically in 2018, driven by XIFAXAN, which had a great year with 22% growth. Great results from our 2 largest segments. Delivering on commitments is important to us.
Salix 在 2018 年有機成長 12%,主要由 XIFAXAN 帶動;XIFAXAN 表現亮眼,成長 22%。我們兩個最大事業部交出優異成果。履行承諾對我們而言非常重要。
On Slide 6, we show how we perform against the guidance we provided 1 year ago, in February 2018. A year ago, we promised to deliver 2018 revenues in the range of $8.1 billion to $8.3 billion. We actually delivered $8.38 billion. A year ago, we promised to deliver adjusted EBITDA in the range of $3.05 billion to $3.2 billion. We delivered $3.47 billion.
在第 6 頁投影片,我們展示相較於一年前(2018 年 2 月)所提供指引的達成情況。一年前,我們承諾 2018 年營收將落在 81 億至 83 億美元區間。我們實際達成 83.8 億美元。一年前,我們承諾調整後 EBITDA 將落在 30.5 億至 32 億美元區間。我們達成 34.7 億美元。
Paul will walk you through the fourth quarter and the full year results in more detail. So with that, I'll turn it over to Paul.
Paul 將更詳細帶各位檢視第四季與全年結果。那麼,我把時間交給 Paul。
Paul S. Herendeen - Executive VP & CFO
Paul S. Herendeen - Executive VP & CFO
Thank you, Joe, I'm going to start on Slide 7, the top level financial results for the quarter. Before I begin, I want to point out that when we talk about organic growth, that means on a constant-currency basis and removing the impact of divestitures and discontinuations in the comparative period.
謝謝你,Joe。我將從第 7 頁投影片開始,先看本季的整體財務結果。在開始之前,我想指出,當我們談到有機成長時,指的是以固定匯率基礎計算,並剔除比較期間內出售資產與停產的影響。
One other note, on the Q3 call, I referenced our initiative to reduce the level of channel inventories of our branded U.S. pharma products that would have the effect of reducing our revenues in Q4 and for the full year 2018 by an estimated $100 million. As it turned out, the actual result was a $76 million drag on revenue that was spread across all 4 of our segments. I'm going to reference this item a lot, and we've included a slide in the appendix that shows the impact on revenue and profit by segment.
另外補充一點,在第三季電話會議上,我提到我們降低美國品牌處方藥產品通路庫存水位的計畫,該計畫預估會使我們第四季及 2018 全年營收減少約 1 億美元。結果實際上對營收的拖累為 7,600 萬美元,且分散在我們四個事業部之中。我會經常提到這個項目,我們也在附錄中加入一張投影片,顯示其對各事業部營收與獲利的影響。
Okay. Let's go. We had a very strong finish to 2018. We posted our fourth consecutive quarter of organic growth despite the completed channel inventory reduction.
好的。我們開始。我們在 2018 年收尾表現非常強勁。儘管已完成通路庫存降低,我們仍繳出連續第四季的有機成長。
Q4 revenue was up 1% organically and would have been up 5% but for the channel inventory reduction, good stuff. The B + L segment comprising 57% of our revenue was up 5% organically, with 4 of the 5 businesses within that segment delivering organic growth.
第四季營收有機成長 1%;若非通路庫存降低,本可有機成長 5%,表現不錯。B + L 事業部占我們營收的 57%,有機成長 5%,且該事業部五項業務中有四項實現有機成長。
Salix was up 1% organically despite the dramatic impact of the channel inventory reduction on the Salix segment. Ortho Derm was down 2% and Diversified was down 9% organically. Stepping down to gross profit and gross margin, we post a 150 basis point improvement in gross margin. A good chunk of the improvement was due to mix, but we also realized a meaningful improvement in our supply chain efficiency, driven by the ongoing efforts of Dennis Asharin, our Head of Global Manufacturing, and his team. Over the last couple of years, the manufacturing team working together with Dr. Louis Yu in our quality organization, have been implementing a right-first-time ethos that has decreased costs and reduced supply chain disruptions.
儘管通路庫存去化對 Salix 事業部造成顯著衝擊,Salix 仍以有機口徑成長 1%。Ortho Derm 有機下滑 2%,Diversified 有機下滑 9%。往下看至毛利與毛利率,我們的毛利率提升了 150 個基點。改善的很大一部分來自產品組合(mix),但我們也在供應鏈效率上實現了顯著提升,這得益於全球製造負責人 Dennis Asharin 及其團隊持續推動的努力。過去幾年,製造團隊與品質組織的 Louis Yu 博士協同合作,推行「一次就做對(right-first-time)」的理念,降低了成本並減少了供應鏈中斷。
Down in operating expenses, if you look at the reported selling, advertising and promotion line, it looks like we reduced those expenses by 4%. But adjusting for currency and divested businesses in the prior year, we actually spent more on our go-forward business in Q4 of '18 versus '17, mainly additional sales resources and promotional dollars to drive longer-term growth. This will be a theme for us in 2019, and that's why I'm framing it for you here.
在營業費用方面,如果你看報表中的銷售、廣告與促銷(selling, advertising and promotion)項目,看起來我們將這些費用降低了 4%。但若剔除匯率影響以及前一年已剝離業務的影響,我們在 2018 年第四季相較 2017 年第四季,實際上在未來核心業務(go-forward business)上投入更多,主要是增加銷售資源與促銷預算,以推動更長期的成長。這將是我們 2019 年的一個主題,因此我在此先為各位鋪陳。
G&A was flat on a constant-currency basis and reflects our ongoing efforts to control costs that don't directly drive revenue. Investment in R&D, meanwhile, was up $30 million compared with Q4 of '17. Consistent and increase investment in R&D is a significant part of the ongoing transformation of our company and is integral to our ability to drive long-term organic growth across our core businesses.
G&A 以固定匯率口徑來看持平,反映我們持續致力於控管那些不直接帶動營收的成本。同時,研發(R&D)投資較 2017 年第四季增加了 3,000 萬美元。持續且增加的研發投入,是公司持續轉型的重要一環,也是我們在核心業務中推動長期有機成長能力的關鍵。
At the operating profit lines, adjusted EBITA and adjusted EBITDA, we were basically flat organically versus the prior year quarter. Pretty impressive if you think about the $30 million year-over-year increase investment in R&D and the $65 million negative impact of the channel inventory reduction. Below operating profit, net interest expense was down versus Q4 of '17 by $33 million and our tax rate on adjusted earnings was 3.2% versus 5.8% in the prior year. Those items account for our Q4 adjusted net income growing at a faster pace than operating earnings. As I said earlier, a good strong finish to 2018.
在營業利益層級,調整後 EBITA 與調整後 EBITDA 相較去年同期,以有機口徑基本持平。若考量研發投資年增 3,000 萬美元,以及通路庫存去化帶來 6,500 萬美元的負面影響,這樣的表現相當令人印象深刻。在營業利益以下,淨利息費用較 2017 年第四季減少 3,300 萬美元,而調整後盈餘的稅率為 3.2%,相較前一年為 5.8%。這些因素使我們第四季調整後淨利的成長速度快於營業盈餘。如我先前所說,2018 年以一個強勁的收尾作結。
As I go through the 4 segments, I'm going to focus mainly on revenue. Starting on Slide 8, with B + L/International. Really good quarter, 4 of the 5 businesses delivered organic growth and the one that didn't, Global Optho Rx, would have grown 5% if not for the channel inventory reduction. From a growth perspective, Global Vision Care was the star, up 12% organically led by the U.S. business that was up 23%, driven by the impact of increased promotional resources we deployed beginning back in 2017 and the successful launch of expanded parameters of Biotrue ONEday toric. International Vision Care also delivered strong growth, up 8%, driven by strength in SofLens daily disposables, ultra-monthly SPS and cosmetic lenses. Geographically, International Vision Care was up 11% organically in China and 9% organically in Japan.
接下來我會依序說明 4 個事業部,主要聚焦在營收。先從投影片 8 的 B + L/International 開始。這是一個非常好的季度,5 個業務中有 4 個實現有機成長;而未成長的那一個——Global Optho Rx——若非通路庫存去化,本來會成長 5%。就成長動能而言,Global Vision Care 是明星業務,有機成長 12%,其中美國業務成長 23%,主要受惠於我們自 2017 年起增加的促銷資源投入,以及 Biotrue ONEday toric 擴大參數的成功上市。International Vision Care 亦交出強勁成長,有機成長 8%,動能來自 SofLens 日拋、ultra-monthly SPS 與彩色隱形眼鏡。以地區來看,International Vision Care 在中國有機成長 11%,在日本有機成長 9%。
Global Surgical was up 4% organically, up 6% outside the United States and plus 1% in the U.S. A quick comment here. The international surgical business representing roughly 70% of Global Surgical has delivered consistent organic growth over the last 7 to 8 quarters, while the U.S. surgical business only recently returned to growth in the second half of 2018.
Global Surgical 有機成長 4%;美國以外地區成長 6%,美國成長 1%。這裡快速補充一句。國際手術業務約占 Global Surgical 的 70%,在過去 7 到 8 個季度持續交出穩定的有機成長;而美國手術業務則是在 2018 年下半年才剛重新回到成長。
As the U.S. part of the business continues to deliver more consistent results, the Global Surgical business can deliver better growth that we've observed over the last 2 years.
隨著美國業務持續交出更一致的成果,Global Surgical 有望實現比過去兩年所見更佳的成長表現。
The Global Consumer business was up 4% organically, led by the U.S., that was up 8% on strength in our eye vitamins and the successful launch of LUMIFY. Outside the United States, consumer was up 1% as strength in our Latam cluster from new product launches was partly offset by lower demand for our topical products in Russia. The Global Ophtho Rx business declined 1% organically on a 4% volume decline, driven entirely by the channel inventory reduction in the U.S. The Global Ophtho Rx business would have grown 5% versus Q4 of '17, but for that channel inventory reduction and that growth would have been basically split between increased volume and increased net realized selling prices.
Global Consumer 業務有機成長 4%,由美國市場帶動;美國成長 8%,主要受惠於眼部維他命的強勁表現以及 LUMIFY 的成功上市。在美國以外地區,消費者業務成長 1%;拉美集群因新產品上市帶來的強勢表現,部分被俄羅斯對我們外用產品需求下降所抵銷。Global Ophtho Rx 業務有機下滑 1%,其中銷量下滑 4%,完全由美國通路庫存去化所致。若非該通路庫存去化,Global Ophtho Rx 相較 2017 年第四季本可成長 5%,且該成長基本上會由銷量增加與淨實現售價(net realized selling prices)提升各占一半所構成。
International Pharma, which is our branded generics business in Eastern Europe, Russia, Canada, Africa, Middle East and Latam, rebounded after 4 quarters of subpar performance.
International Pharma(我們在東歐、俄羅斯、加拿大、非洲、中東與拉美的品牌學名藥業務)在連續 4 個季度表現不佳後出現反彈。
You may recall that I previously called out some of the challenges we faced in our Eastern European Russian cluster and that I suggested we would start to see improvement there based on changes we made in organization and leadership. While it's too soon to declare victory, our Russian business turned around from being a growth drag earlier in the year to being a significant contributor to the 8% organic growth of this business in Q4. A quick tip of the hat to John Connolly and Vladimir Gudkov for their efforts. Meanwhile, in Africa/Middle East, that cluster continues to deliver strong growth led by Amoun, which was up 25% organically for the quarter and 19% for the full year.
各位或許記得,我先前曾提到我們在東歐與俄羅斯集群面臨的一些挑戰,並表示基於我們在組織與領導層所做的調整,應該會開始看到改善。雖然現在宣告勝利仍言之過早,但我們的俄羅斯業務已從年初的成長拖累,轉為第四季推動該業務有機成長 8% 的重要貢獻者。在此向 John Connolly 與 Vladimir Gudkov 的努力致意。同時,在非洲/中東方面,該集群持續交出強勁成長,由 Amoun 帶動;Amoun 本季有機成長 25%,全年有機成長 19%。
We have a great team at Amoun, and we look forward to seeing that team leverage its competitive strengths to drive increased business not only in Egypt but ultimately, in other Middle Eastern markets. On to Slide 9, in Salix. Salix took the brunt of the impact of the planned channel inventory reduction, $47 million, and absorbed the impact of the mid-year loss of the exclusivity of UCERIS and still delivered 1% organic growth.
Amoun 擁有一支非常優秀的團隊,我們期待該團隊運用其競爭優勢,推動業務不僅在埃及成長,最終也能拓展至其他中東市場。接著看投影片 9,Salix。Salix 承受了計畫性通路庫存去化的主要衝擊(4,700 萬美元),也吸收了年中 UCERIS 失去獨占權的影響,但仍交出 1% 的有機成長。
Excluding the channel inventory reduction, Salix would have grown 12% versus Q4 '17, driven by XIFAXAN where TRxs were up 8% in the quarter versus the prior year quarter. The nidus of Salix' performance is the team, including Mark McKenna, Nicola Kayel and Josh Coyle. They have performed at a very high level. Note that the Salix segment was one of the major beneficiaries of our improved gross profit margin, up some 290 basis points versus Q4 '17, due to mix and manufacturing efficiencies.
若排除通路庫存去化,Salix 相較 2017 年第四季本可成長 12%,主要由 XIFAXAN 帶動;本季 TRxs 較去年同期成長 8%。Salix 表現的核心在於團隊,包括 Mark McKenna、Nicola Kayel 與 Josh Coyle。他們的表現維持在非常高的水準。請注意,Salix 事業部也是我們毛利率改善的主要受益者之一;相較 2017 年第四季提升約 290 個基點,原因在於產品組合與製造效率提升。
On to Slide 10, in the Ortho Dermatologics segment. The segment was down 2% organically, as spectacular growth in Global Solta was more than offset by an 11% decline in the medical dermatology business. Solta was up 32%, driven mainly by the successful rollout of Thermage FLX, but also basic better fundamental performance across many of our regions under the terrific leadership of Tom Hart and his canorous Aussie accent.
接著看投影片 10,Ortho Dermatologics 事業部。該事業部有機下滑 2%,因 Global Solta 的亮眼成長,仍不足以抵銷醫學皮膚科業務下滑 11% 的影響。Solta 成長 32%,主要由 Thermage FLX 的成功推廣所帶動,同時也反映在 Tom Hart 的卓越領導以及他那富有歌唱般韻律的澳洲口音之下,我們在多個地區的基本面表現全面改善。
To wrap up the Q4 segment discussion, turn to Slide 11 in the Diversified Products. The segment was down 9% organically. Absent the channel inventory reduction, Diversified would have been down a rather modest 5% organically. Pretty good when considering the $41 million drag from the LOE products versus Q4 of '17 fell in the neuro segment there -- business there. Our generics business was a star performer based on 2 factors. First, the launch of authorized generics for our branded products that lost exclusivity. In Q4 '18 versus Q4 '17, the big contributors were UCERIS AG and Elidel AG. And second, the generics team led by Mary Saharyan worked closely with our supply chain to capitalize on market opportunities across our generics portfolio, not just in the quarter, but throughout the year. The generics business was up 18% versus Q4 '17 mostly on volume, but we were able to get some positive contribution from price too, a really good job.
為了總結第四季分部討論,請看多元化產品(Diversified Products)的第 11 張投影片。該分部有機下滑 9%。若不計通路庫存去化,多元化產品的有機降幅本來僅約 5%。考量到相較於 2017 年第四季,LOE 產品帶來 4,100 萬美元的拖累(當時在神經分部那邊——那項業務),這表現相當不錯。我們的學名藥業務基於兩個因素成為亮點。第一,是我們失去獨家權的品牌產品推出授權學名藥(authorized generics)。在 2018 年第四季相較 2017 年第四季,主要貢獻者是 UCERIS AG 與 Elidel AG。第二,由 Mary Saharyan 領導的學名藥團隊與我們的供應鏈密切合作,把握我們學名藥產品組合中的市場機會,不僅在該季度,而是貫穿全年。學名藥業務相較 2017 年第四季成長 18%,主要來自銷量,但我們也能從價格端取得一些正向貢獻,做得非常好。
Flip to the full year 2018 versus '17 on Slide 12. The themes are similar to what we saw in Q4. Revenue was up 2% on an organic basis and would have been up 3% but for the $76 million impact of the completed channel inventory reduction. Salix led the way from a growth perspective, up 12%, would have been 15% if not for the channel inventory reduction. We posted really strong growth with XIFAXAN, APRISO and the RELISTOR franchise that was slightly offset by the impact of the July LOE for UCERIS. B + L/International was up 4% organically versus 2017 with all 5 businesses delivering organic growth. The Ortho Dermatologics segment was down 13%, as Global Solta's plus 22% growth versus the prior year was more than offset by the continued rebasing of the medical dermatology business.
接著看第 12 張投影片,2018 全年相較 2017 年。主題與我們在第四季看到的相似。營收以有機基礎成長 2%,若非已完成的通路庫存去化造成 7,600 萬美元影響,本來會成長 3%。從成長角度看,Salix 表現領先,有機成長 12%;若不計通路庫存去化,將為 15%。XIFAXAN、APRISO 與 RELISTOR 系列帶來非常強勁的成長,但 7 月 UCERIS 的 LOE 影響略為抵銷。B + L/International 相較 2017 年有機成長 4%,五個業務皆實現有機成長。Ortho Dermatologics 分部下滑 13%;儘管 Global Solta 相較前一年成長 22%,但仍被醫學皮膚科業務持續重置基期(rebasing)所抵銷。
Finally, Diversified posted a 5% organic decline, modest compared with the 24% decline we saw in 2017 as the growth drag of the LOE assets moderated in 2018 and was offset in part by the solid 19% growth in the generics business. Note the gross margin improvement versus 2017, roughly 110 basis points, same things as we saw in Q4, mix and supply chain efficiency.
最後,多元化產品(Diversified)有機下滑 5%,相較於 2017 年我們看到的 24% 下滑要溫和得多,因為 2018 年 LOE 資產的成長拖累趨緩,並部分被學名藥業務穩健的 19% 成長所抵銷。請注意毛利率相較 2017 年改善,約 110 個基點;原因與第四季相同,來自產品組合(mix)與供應鏈效率。
We reduced G&A by some 6% on a constant-currency basis, partly on reduced legal expenses. Finally, we increased our investment in R&D by some 15%, with the expectation that we'll continue to invest more in R&D in 2019 versus '18.
我們以固定匯率基礎將 G&A 降低約 6%,部分原因是法律費用下降。最後,我們將研發(R&D)投資提高約 15%,並預期 2019 年相較 2018 年將持續加大研發投入。
Adjusted EBITDA was up 3% organically to $3.474 billion despite the $65 million drag of the completed channel inventory reduction. Pretty good, right? Adjusted net income grew faster organically than adjusted EBITDA as our net interest expense decreased $154 million compared with 2017, due to our successful and continuing efforts to reduce debt. And we saw a decrease in our tax rate on adjusted pretax earnings from 13.2% in 2017 to 8.4% in 2018.
儘管已完成的通路庫存去化帶來 6,500 萬美元拖累,調整後 EBITDA 仍以有機基礎成長 3%,達 34.74 億美元。相當不錯,對吧?調整後淨利以有機基礎成長速度快於調整後 EBITDA,因為相較 2017 年,我們的淨利息費用減少 1.54 億美元,源於我們成功且持續的降債努力。同時,我們的調整後稅前盈餘有效稅率從 2017 年的 13.2% 降至 2018 年的 8.4%。
Turning to the balance sheet summary slide on Slide 13. You see the progression of our debt balance since last year. Debt is down $1.12 billion from the end of 2017. We ended the year with $24.6 billion of debt, $723 million of cash and a modest $75 million outstanding under our revolving credit facility. After year-end, we did prepay another $100 million of debt.
接著看第 13 張投影片的資產負債表摘要。你會看到自去年以來我們債務餘額的變化趨勢。債務較 2017 年底減少 11.2 億美元。我們年底的債務為 246 億美元,現金 7.23 億美元,循環信貸額度(revolving credit facility)動用未償餘額為溫和的 7,500 萬美元。年後我們又提前償還了 1 億美元債務。
On to Slide 14, and our cash flow summary. Cash provided by operating activities for the full year totaled $1.501 billion. In the first half of the year, the settlement of several legacy legal cases reduced that amount by roughly $225 million. So for the year, our cash provided by operating activities was in line with our expectations.
接著看第 14 張投影片,我們的現金流摘要。全年營運活動提供的現金合計 15.01 億美元。在上半年,數起歷史遺留法律案件的和解使該金額減少約 2.25 億美元。因此全年營運活動提供的現金符合我們的預期。
Sequentially, our cash provided by operating activities went from $522 million in Q3 to $319 million in Q4. Note that as a result of refinancing debt, roughly 1/3 of our cash interest is now paid in each of Q2 and Q4. Looking backward, the settlement of interest had been relatively consistent across the 4 quarters. This change had a meaningful impact on the phasing of cash generated by operating activities in Q4 versus Q3 and that will continue in the future.
按季來看,營運活動提供的現金從第三季的 5.22 億美元降至第四季的 3.19 億美元。請注意,由於債務再融資,我們約三分之一的現金利息現在分別在第二季與第四季支付。回顧過去,利息結算在四個季度之間相對一致。這項變動對第四季相較第三季的營運活動現金生成時點(phasing)造成顯著影響,且未來將持續如此。
Shifting to our guidance for 2019. The particulars of our guidance are spelled out on Slide 15. The highlights, we're expecting revenue in the range of $8.3 billion to $8.5 billion and adjusted EBITDA in the range of $3.35 billion to $3.50 billion. Our guidance implies organic revenue growth in the range of flat to plus 3% and organic growth of adjusted EBITDA from minus 2% to plus 2% when compared with 2018.
接著談我們對 2019 年的指引。指引的細節列在第 15 張投影片。重點是:我們預期營收介於 83 億至 85 億美元,調整後 EBITDA 介於 33.5 億至 35.0 億美元。我們的指引意味著相較 2018 年,有機營收成長介於持平至 +3%,調整後 EBITDA 的有機成長介於 -2% 至 +2%。
There's a bridge from 2018 actuals to our guidance on Slide 16.
第 16 張投影片提供從 2018 年實際數到我們指引的銜接(bridge)。
The very strong finish to 2018 took a bit of the top off of our growth expectations for 2018, but we'll take the good performance that we put on the board and move forward. And adjusted EBITDA, when looking at 2019 versus 2018, bear in mind that our guidance contemplates an approximately 10% or $40 million increase in investment in R&D and meaningful increases in selling and promotional expenses to support our recently launched and to be launched brands. If we were managing solely to deliver near-term growth of adjusted EBITDA, I have no doubt that we could put a higher EBITDA range on the board for 2019.
2018 年非常強勁的收尾,讓我們對 2018 年的成長預期上緣略為收斂,但我們會接受這份亮眼表現並繼續前進。至於調整後 EBITDA,在比較 2019 年與 2018 年時,請記住我們的指引納入研發投資約增加 10%(或 4,000 萬美元),以及為支持我們近期已上市與即將上市的品牌而大幅增加銷售與推廣費用。如果我們只以交付調整後 EBITDA 的短期成長為唯一管理目標,我毫不懷疑我們可以為 2019 年提出更高的 EBITDA 區間。
But we're playing the longer game, and that means sacrificing a bit of near-term profits to deliver a better, more valuable future.
但我們是在打長期戰,這意味著犧牲一些短期利潤,以換取更好、更有價值的未來。
I want to call your attention to some other guidance details included on the slide. You see that we expect to increase CapEx in 2019. This is mainly growth CapEx for our initiative to introduce new daily silicone hydrogel lenses, but also to fund the overdue build-out of our global IT infrastructure. We've also added a few new line items to our guidance slide, namely our expected gross profit margin, which we expect to be in the range of 71% to 72% in 2019, and our expected full year cash generated from operations, which we expect to be in the range of $1.5 billion to $1.6 billion.
我想請各位注意投影片中包含的其他指引細節。你會看到我們預期 2019 年將提高資本支出(CapEx)。這主要是為了我們推出新款每日拋矽水膠(silicone hydrogel)隱形眼鏡的計畫所需的成長型資本支出,同時也用於補上延宕已久的全球 IT 基礎設施建置。我們也在指引投影片新增了幾個項目,包括預期毛利率;我們預期 2019 年毛利率介於 71% 至 72%;以及預期全年營運產生的現金,我們預期介於 15 億至 16 億美元。
Note that our reported gross margin is sensitive to changes in FX rates, so please bear that in mind. Finally, we believe that on a constant-currency basis and for the midpoints of our 2019 guidance, we can grow over the next 3 years to 2022 at compound annual growth rates of between 4% to 6% for revenue and 5% to 8% for adjusted EBITDA. That's it for me, Joe.
請注意,我們所報告的毛利率對外匯匯率變動相當敏感,因此請將此納入考量。最後,我們相信以固定匯率基礎並以我們2019年指引的中位數來看,在未來3年到2022年,我們可實現營收4%至6%、調整後EBITDA 5%至8%的複合年成長率。我就講到這裡,Joe。
Joseph C. Papa - CEO & Chairman of the Board
Joseph C. Papa - CEO & Chairman of the Board
Thank you, Paul. Moving now to Page 17, our Bausch + Lomb business is a fully integrated eye health business with offerings across the spectrum of vision care, which include contact lenses, surgical, consumer products and prescription ophthalmology. Importantly, this integrated business is being driven by several global megatrends that we see creating increased demand for our eye health products. First, recent statistics indicate that there are approximately 1.3 billion people in the world who live with some kind of vision impairment and 80% of all vision impairment is generally considered to be avoidable. Another megatrend is the graying of the United States population as the baby boomers hit age 65 and above. People over the age of 65 use 8x as many eye care products than those under the age of 65. Clearly, an important megatrend. In addition, the prevalence of myopia or nearsightedness is increasing to epidemic levels. As the graph shows, myopia rates in Hong Kong are steadily increasing from about 30% of those born before 1950 to a staggering 87% of those born in the last 20 or so years. This data suggests that environmental factors like increased screen time with laptops, cellphones are responsible for the high rates of myopia we are seeing in Hong Kong and in other parts of the world.
謝謝你,Paul。接著看第17頁,我們的Bausch + Lomb業務是一個完全整合的眼健康業務,提供涵蓋視力照護全光譜的產品與服務,包括隱形眼鏡、手術、消費性產品以及處方眼科用藥。重要的是,我們看到這個整合型業務正受到數個全球性巨型趨勢所驅動,這些趨勢正在帶動對我們眼健康產品的需求增加。第一,最新統計顯示,全球約有13億人有某種形式的視力障礙,而所有視力障礙中有80%一般被認為是可避免的。另一個巨型趨勢是美國人口老化,因為嬰兒潮世代邁入65歲及以上。65歲以上的人使用的眼部照護產品是65歲以下者的8倍。顯然,這是一個重要的巨型趨勢。此外,近視(myopia)或短視的盛行率正上升至流行病等級。如圖所示,香港的近視率正穩步上升,從1950年前出生者約30%,到過去約20年出生者驚人的87%。這些數據顯示,像是使用筆電、手機等螢幕時間增加等環境因素,是我們在香港及世界其他地區所見高近視率的原因。
Myopia statistics are important to our business for obvious reasons, but also because myopia is a risk factor for glaucoma, macular degeneration and retinal detachment.
近視統計對我們的業務很重要,原因顯而易見;此外,近視也是青光眼、黃斑部退化以及視網膜剝離的風險因子。
Based on these megatrends, we are projecting growing demand for eye care, and we believe Bausch & Lomb as a global integrated eye health business is well positioned to provide them.
基於這些巨型趨勢,我們預期眼部照護需求將持續成長;我們相信,作為全球整合型眼健康業務的Bausch & Lomb,具備良好條件來滿足這些需求。
On Slide 18, the B&L segment delivered its ninth consecutive quarter of organic growth, generating 2 years of mid-single-digit growth organically. E-commerce sales through Amazon grew by 64% in 2018 versus 2017. And we saw a 44% spike in the sales at a B&L flagship store and Alibaba Singles’ Day during the fourth quarter. The performance of our Global Vision Care has been phenomenal. Driven by Biotrue ONEday and Bausch + Lomb ULTRA, the U.S. business significantly outperformed the market, up 13% versus 2019 compared to 4% to 5% growth for the rest of the industry.
在第18張投影片,B&L部門連續第九個季度實現有機成長,並在過去2年有機達成中個位數成長。2018年透過Amazon的電商銷售較2017年成長64%。而在第四季,我們在B&L旗艦店以及阿里巴巴雙11期間的銷售出現44%的激增。我們全球視力照護業務的表現非常亮眼。在Biotrue ONEday與Bausch + Lomb ULTRA的帶動下,美國業務顯著優於市場表現,成長13%,相較之下產業其他公司成長約4%至5%。
Moving now to Global Consumer, LUMIFY, which was launched in May, is now the #1 product in the Redness Reliever category with approximately 28% market share. LUMIFY is also #1 product recommended by optometrists and ophthalmologists for redness relief. The B + L eye vitamins, PreserVision and Ocuvite, grew organically by 7% in 2018 on a combined basis.
接著看全球消費品業務,LUMIFY於5月上市,目前在去紅血絲(Redness Reliever)品類中為第1名產品,市占率約28%。LUMIFY同時也是驗光師與眼科醫師在去紅血絲方面最推薦的第1名產品。B + L的眼部維他命產品PreserVision與Ocuvite在2018年合計有機成長7%。
Finally, in global ophthalmology, VYZULTA TRx weekly prescriptions grew by more than 50% sequentially in the fourth quarter of 2018 versus the third quarter 2018. Also, we know the data tells us that patients who start on VYZULTA are 34% more likely to stay on it than other branded agents, which brings us to market access, where our position has substantially improved versus earlier in 2018.
最後,在全球眼科用藥方面,VYZULTA的TRx每週處方量在2018年第四季相較第三季連續成長超過50%。此外,數據也顯示,開始使用VYZULTA的患者,相較其他品牌藥物,持續使用的可能性高出34%;這也帶到市場准入方面,我們的地位相較2018年較早時期已有顯著改善。
We are now up to 80% commercial coverage and Part D coverage is up to about 30%. However, more than half of the Part D prescriptions are being covered today. We are making good progress here.
我們目前的商業保險覆蓋率已達80%,而Part D覆蓋率提升至約30%。不過,目前超過一半的Part D處方已獲得給付。我們在這方面進展良好。
Finally, VYZULTA was approved to the second market, Canada, last month. So we believe the product has good momentum and a lot of opportunity ahead.
最後,VYZULTA上個月已獲核准進入第二個市場——加拿大。因此我們認為該產品動能良好,未來仍有很大的機會。
Over to Slide 19, I want to emphasize the strength of our international business which ties into the megatrends I mentioned earlier. As you can see from the map, our branded franchises have market-leading positions throughout Canada, Latin America, Europe, Middle East, Africa and importantly, Asia. Bausch + Lomb Vision Care is the leader in key emerging markets like China, Thailand and India, which represent approximately 40% of the world's population and are among the fastest-growing markets.
接著看第19張投影片,我想強調我們國際業務的強勁實力,這也與我先前提到的巨型趨勢相呼應。如地圖所示,我們的品牌事業在加拿大、拉丁美洲、歐洲、中東、非洲,以及尤其是亞洲,皆具備市場領先地位。Bausch + Lomb Vision Care在中國、泰國與印度等關鍵新興市場居於領導地位;這些市場約占全球人口的40%,且是成長最快的市場之一。
The key takeaways I want to emphasize that approximately 58% of our business is not currently exposed to U.S.-branded prescription pricing.
我想強調的重點是,我們約58%的業務目前並未暴露於美國品牌處方藥定價的影響之下。
Turning now to Slide 20, we've given a sense of the near-term product pipeline across the entire eye health business. I'll summarize by saying that Bausch & Lomb is a diversified and fully integrated eye care business, our integrated eye -- our integrated platform is a significant strength for us, particularly given the trends that we expect to drive global eye care consumption. And as you can see from this slide, we have a number of great opportunities in our pipeline that we believe will enable us to grow at a mid-single-digit growth rate.
接著看第20張投影片,我們已就整體眼健康業務的短期產品研發管線提供概覽。我總結一下:Bausch & Lomb是一個多元化且完全整合的眼部照護業務;我們的整合平台——我們的整合式平台——是我們的重要優勢,特別是在我們預期將推動全球眼部照護消費的趨勢之下。如本頁所示,我們的研發管線中有多項很好的機會,我們相信這將使我們能以中個位數的成長率持續成長。
Moving now to Salix highlights on Slide 21. Let's start with XIFAXAN. I want to provide perspective on the reported 2018 revenue growth of 22%, which is 1/3 of the volume came from strong TRx gains, volume gains. 1/3 from our Project CORE activities that improved gross to net with better co-pays, couponing and rebates.
接著看第21張投影片的Salix重點。先從XIFAXAN開始。我想就2018年所報告的22%營收成長提供一些觀點,其中約1/3的量來自強勁的TRx增長、銷量增長。另1/3來自我們的Project CORE活動,透過更好的自付額(co-pays)、優惠券與回扣,改善了gross-to-net。
And about 1/3 falls in the category of gross pricing improvements. We think, though that we are just scratching the surface at XIFAXAN when you consider that chart on the right, which shows that 90% of the IBS-D market is still being treated by antispasmodic or antidiarrheals. In other words, 90% of the market represents a significant growth opportunity for XIFAXAN in IBS-D. Finally, we expanded our GI business by obtaining rights to other copromote products. LUCEMYRA, DOPTELET and PLENVU complement our existing products, and we expect these additional offerings to help drive revenue growth.
另外約1/3屬於毛定價(gross pricing)改善的範疇。不過,當你看右側那張圖表時,我們認為XIFAXAN在IBS-D上的潛力才剛開始被開發;圖表顯示,IBS-D市場中仍有90%是以解痙藥或止瀉藥治療。換言之,這90%的市場代表XIFAXAN在IBS-D領域的重大成長機會。最後,我們透過取得其他共同推廣產品的權利,擴大了我們的腸胃(GI)業務。LUCEMYRA、DOPTELET與PLENVU可補強我們既有產品組合,我們預期這些新增產品將有助於帶動營收成長。
Let's move on to Slide 22 and talk about the Salix pipeline. We're continuing our R&D investment in rifaximin by developing a number of new formulations and importantly, new indications that we listed on the chart. We have great opportunities with XIFAXAN.
讓我們繼續到第22頁,談談 Salix 的產品研發管線。我們持續加大對利福昔明(rifaximin)的研發投資,開發多種新劑型,且更重要的是,開發圖表中所列的新適應症。我們在 XIFAXAN 上擁有很大的機會。
We also have a potential bolt-on acquisition opportunity that we are excited about. We entered into a stalking horse agreement to acquire certain assets of Synergy Pharmaceuticals, TRULANCE for chronic constipation in IBS-C and also an investigational compound, dolcanatide, which has demonstrated proof of concept in treating patients with multiple GI conditions.
我們也有一個令我們振奮的潛在補強型併購機會。我們已簽訂「stalking horse」協議,擬收購 Synergy Pharmaceuticals 的部分資產,包括用於 IBS-C 相關慢性便秘的 TRULANCE,以及一項研究中化合物 dolcanatide;該化合物已在治療多種腸胃道(GI)疾病患者方面展現概念驗證(proof of concept)。
We think these assets are a natural fit to what we are already doing in gastroenterology and primary care. And we have some capabilities in terms of scale, supply chain and managed care expertise that can help improve the performance of TRULANCE.
我們認為這些資產與我們目前在腸胃科與基層醫療領域所做的事情高度契合。此外,我們在規模、供應鏈以及受管醫療(managed care)專業方面具備能力,可協助提升 TRULANCE 的表現。
If we are successful, we expect the transaction to close in March 2019.
若我們順利完成,我們預期該交易將於2019年3月完成交割。
Moving on to Slide 23, Ortho Dermatologics. While this segment has trailed B + L/International Salix turnaround, the business continues to stabilize as we launch new products.
接著看第23頁,Ortho Dermatologics。雖然該事業部落後於 B + L/International 以及 Salix 的復甦進程,但隨著我們推出新產品,業務持續趨於穩定。
SILIQ generated $6 million of sales in the fourth quarter and as you can see from the chart on the right, TRx weekly scripts grew more than 30% TRx growth in fourth quarter 2018 versus the prior quarter.
SILIQ 在第四季創造了600萬美元的銷售額;如右側圖表所示,2018年第四季的每週 TRx 處方量較前一季成長超過30%。
We also launched 2 products -- new products during the fourth quarter, ALTRENO, an innovative new retinoid acne treatment, and BRYHALI, a new potent steroid treatment for plaque psoriasis.
我們也在第四季推出了2項新產品——ALTRENO,一款創新的新型維A酸類(retinoid)痤瘡治療;以及 BRYHALI,一款用於斑塊型乾癬的全新高效類固醇外用治療。
Our aesthetics business, Global Solta, was a bright spot driven by strong -- by the strength in the U.S., Korea and Taiwan and the expected global launch of Thermage FLX. We also have announced a transformational new model for our dermatology products in the U.S. that we believe will give us an opportunity to grow the overall business. The business will pursue 2 separate access models. Reimbursed medical dermatology, which is a continuation of our current model and cash pay prescription dermatology.
我們的醫美業務 Global Solta 表現亮眼,主要受美國、韓國與台灣的強勁動能,以及 Thermage FLX 預期的全球上市所帶動。我們也宣布在美國針對皮膚科產品採用一個具變革性的全新模式,我們相信這將帶來整體業務成長的機會。該業務將採行兩種不同的通路/給付模式。一是可報銷的醫療皮膚科(reimbursed medical dermatology),延續我們目前的模式;二是自費處方皮膚科(cash pay prescription dermatology)。
In light of the challenging payer environment for dermatology products, we believe this new cash pay prescription model offers improved, predictable and sustainable fulfillment options.
鑑於皮膚科產品所面臨的嚴峻支付方環境,我們認為這個新的自費處方模式可提供更佳、可預測且可持續的履約(fulfillment)選項。
For example, with our new model, adult women who prefer our cosmotic, elegant formulation of 0.05% tretinoin lotion will now be able to get ALTRENO from their dermatologists at a predictable price, which pushed the treatment decision in the hands of the doctor and the patient.
例如,在我們的新模式下,偏好我們0.05%維A酸(tretinoin)乳液之化妝品級、優雅配方的成年女性,將可透過其皮膚科醫師以可預期的價格取得 ALTRENO,讓治療決策回到醫師與病患手中。
On Slide 24, I want to talk about DUOBRII, which upon approval expected to be the first and only topical lotion that contains a unique combination of halobetasol and tazarotene in one formulation for the treatment of plaque psoriasis. We announced on Friday that the FDA is close to finalizing its review, and we expect a decision from the FDA shortly.
在第24頁,我想談談 DUOBRII;若獲核准,預期將成為首款且唯一一款外用乳液,在單一配方中結合獨特的 halobetasol 與 tazarotene,用於治療斑塊型乾癬。我們在週五宣布,FDA 已接近完成審查定案,我們預期很快會收到 FDA 的決定。
We remain optimistic about this opportunity. First, there are about 7.5 million psoriasis patients in the United States and between 150,000 to 260,000 new cases diagnosed each year. Second, research shows that 90% of patients with psoriasis are open to new treatments and third, 85% of the patients on therapy use a topical medication. Our actuarial model suggests that by using DUOBRII, even a small reduction in the number of psoriasis patients that need a biological treatment could result in a fairly large net savings for health plans.
我們對此機會仍保持樂觀。第一,美國約有750萬名乾癬患者,每年新增確診約15萬至26萬例。第二,研究顯示90%的乾癬患者願意嘗試新療法;第三,接受治療的患者中有85%使用外用藥物。我們的精算模型顯示,若使用 DUOBRII,即便僅小幅降低需要生物製劑治療的乾癬患者人數,也可能為健康保險計畫帶來相當可觀的淨節省。
On Slide 25, we show the anticipated revenue growth of our Significant Seven products, 6 of which have been launched today. As the blue bar shows, this group of products represented approximately $75 million of revenue in 2017 and that doubled in 2018 to more than $150 million. We are projecting another double in 2019 to approximately $300 million, with expected peak annualized total revenues of over $1 billion by the end of 2022. We're excited by what this means in terms of being able to launch new products that make a difference in patients' lives.
在第25頁,我們展示「重要七大」(Significant Seven)產品的預期營收成長,其中有6項目前已上市。如藍色長條所示,這組產品在2017年的營收約為7,500萬美元,並在2018年倍增至超過1.5億美元。我們預估2019年將再倍增至約3億美元,並預期到2022年底,年化總營收峰值將超過10億美元。我們對這代表我們能推出真正改善病患生活的新產品感到振奮。
Finally, Slide 26 sets out our expectations for 2019, a year of growth for Bausch Health as we pivot to offense. First and foremost, we expect reported revenue for the total company to grow in 2019 versus 2018 at or above the midpoint of our guidance range in that current FX rate.
最後,第26頁列出我們對2019年的展望:這將是 Bausch Health 轉向主動進攻、實現成長的一年。首先也是最重要的,我們預期在目前匯率(FX)水準下,2019年全公司報告營收將較2018年成長,且成長幅度將達到或高於我們財測區間的中位數。
Second, cash generation. We expect to generate $1.5 billion to $1.6 billion of cash from operations, and we plan to use more than $1 billion of that cash opportunistically to reduce debt and/or fund bolt-on acquisitions. R&D investment is expected to increase by about 10% in 2019 as we continue to develop innovative products that improve patients' lives. Revenue generated by our Significant Seven products is expected to double in 2019 to approximately $300 million.
第二,現金創造。我們預期營運活動將產生15億至16億美元現金,並計畫機會性地使用其中超過10億美元來降低負債及/或資助補強型併購。隨著我們持續開發能改善病患生活的創新產品,2019年的研發投資預期將增加約10%。「重要七大」產品所帶來的營收預期在2019年將倍增至約3億美元。
Our continued efforts to improve operational efficiency, which we refer to internally as Project CORE, are expected to deliver more than $75 million in operating profit in 2019.
我們持續提升營運效率的努力(內部稱為 Project CORE),預期在2019年將帶來超過7,500萬美元的營業利益。
And finally, we're meeting expectations on our previous growth guidance and adding that Bausch Health expects a 3-year compound annual growth rate from the midpoint of our 2019 guidance of 4% to 6% revenue growth and 5% to 8% adjusted EBITDA growth during the period from 2019 to 2022 on a constant-currency basis.
最後,我們不僅達成先前的成長指引預期,並補充說明:以2019年財測中位數為基準,Bausch Health 預期在2019年至2022年期間、以固定匯率(constant-currency)計算,三年期營收年複合成長率(CAGR)為4%至6%,調整後 EBITDA 年複合成長率為5%至8%。
Based on our 2018 results and our outlook for 2019, we believe that Bausch Health is well positioned to continue the momentum that is driving the company's transformation as we now pivot to offense.
基於我們2018年的成果以及對2019年的展望,我們相信 Bausch Health 已具備良好定位,可在轉向主動進攻之際,延續推動公司轉型的成長動能。
With that, operator, let me open up the line for questions.
接下來,接線員,請幫我開放提問。
Operator
Operator
(Operator Instructions) Today's first question comes from Umer Raffat of Evercore ISI.
(接線員指示) 今天的第一個問題來自 Evercore ISI 的 Umer Raffat。
Umer Raffat - Senior MD & Senior Analyst of Equity Research
Umer Raffat - Senior MD & Senior Analyst of Equity Research
I wanted to touch upon 2 topics. First, as we head into 2019, can you -- perhaps this one's for Paul. Paul, can you lay out for us some of the comments you shared at the conference in January, where you talked about growth and 3-year growth CAGRs relative to the roughly flattish guidance? And could you also give us a sense for the amount of growth to net improvement impact that you expect in 2019? And then my second question is, perhaps for Joe. Joe, I know there's like this 300-plus patient trial for XIFAXAN SSD formulation, potentially due at some point this year. Could you walk us through the timing on that? And perhaps more importantly, how meaningful is that indication? Because it's my understanding that it's an acute indication, which only requires a couple of days' worth of administration. So is that a trial and/or an indication that's commercially meaningful?
我想觸及兩個主題。第一,展望2019年,您能否——這題或許給 Paul。Paul,能否為我們說明一下您在1月會議上分享的幾點看法?當時您談到相對於大致持平的財測指引,成長以及三年期成長 CAGR 的相關評論。另外,您也能否讓我們了解您預期2019年「成長」對「淨改善」的影響幅度大概是多少?接著第二個問題,或許給 Joe。Joe,我知道 XIFAXAN 的 SSD 劑型似乎有一項300多名患者的試驗,可能會在今年某個時間點讀出。您能否帶我們了解一下該試驗的時程?以及更重要的是,這個適應症的意義有多大?因為據我了解,這是一個急性適應症,只需要用藥幾天。所以,這項試驗和/或這個適應症在商業上是否具有實質意義?
Joseph C. Papa - CEO & Chairman of the Board
Joseph C. Papa - CEO & Chairman of the Board
Okay. So Paul, why don't you start with that 2019 question and some of the growth in the GTN and back.
好的。那麼,Paul,你何不先從2019年的問題以及GTN的一些成長情況談起,然後再回到其他部分。
Paul S. Herendeen - Executive VP & CFO
Paul S. Herendeen - Executive VP & CFO
Sure. And thanks for the questions, Umer. First of all, on the 3-year growth rate, I think you characterized our guidance as flattish. I mean, I referenced in my remarks it's a challenge for us relative to 2018, as we finished the year really, really strong, which we're happy about. So kind of took a little bit of the top off what you see for '19, but what we essentially done is re-upped our 3-year CAGR guidance to say 4% to 6% for revenue, 5% to 8% for adjusted EBITDA, the midpoint of our 2019 guidance. There are included in our deck here a lot of charts and bridges that point out that FX has been a challenge for us that people look and go, "Oh, where are you relative to that?" I say we're -- yes, we feel like we are continuing to be on track with our longer-range expectations for growth of both revenue and profitability. The big issue for us in 2019, we expect the profitability, I called out. We're investing more in our business. And so you're not seeing that -- see -- you won't see 2019 wherever we end up with respect to revenue. That to translate directly to adjusted EBITDA growth because the increased investment in R&D and the necessary investments behind selling and promotional expenses for our launched and to be launched products. So we feel pretty good about our prospects for delivering growth over the course of the next several years. Your second question was -- I think was around gross to nets and what can you expect. I'd say that we had a very strong year with respect to gross to nets improving that. And I think we called it out on our last call and even at the beginning of the year, we had some things that we were able to successfully change in the nonretail channel. We had a couple -- I am looking to make sure I get it right. About a 200 basis point improvement, if you looked across the company for gross to net in 2018 v. 2017. As we look ahead to 2019 v. '18, we expect -- we would not expect that level of improvement. But we would expect to continue to improve our gross to nets across our portfolio in '19 via '18. Does that answer, Umer?
當然。也謝謝你的提問,Umer。首先,關於3年成長率,我想你把我們的指引形容為大致持平。我的意思是,我在發言中提到,與2018年相比這對我們是個挑戰,因為我們在年末表現非常、非常強勁,這點我們也很高興。所以某種程度上把你在2019年看到的數字「上緣」稍微削掉了一點;但我們基本上是重新確認我們的3年CAGR指引:營收4%到6%,調整後EBITDA 5%到8%,以我們2019年指引的中位數來看。我們的簡報裡包含了很多圖表與銜接分析,指出匯率(FX)一直是我們面臨的挑戰,大家會看了就問:「那你們相對於那個目標在哪裡?」我會說我們——是的,我們覺得我們仍然在更長期的營收與獲利成長預期軌道上。2019年對我們來說最大的議題是獲利能力,我也特別點出來了。我們正在加大對業務的投資。因此你不會看到——你不會看到2019年不論營收最後落在哪裡,都能直接轉化為調整後EBITDA的成長,因為我們增加了研發投資,以及為已上市與即將上市產品所需的銷售與推廣費用投入。所以我們對於未來幾年實現成長的前景感到相當有信心。你的第二個問題——我想是關於gross-to-net,以及你可以期待什麼。我會說,我們在gross-to-net改善方面度過了非常強勁的一年。我想我們在上一次電話會議、甚至在年初就提到,我們在非零售通路成功做了一些調整。我們有幾項——我在確認我說得正確。如果你看整個公司,2018年相較2017年,gross-to-net大約改善了200個基點。展望2019年相較2018年,我們預期——我們不會預期有那種幅度的改善。但我們預期在2019年相較2018年,仍會透過我們的產品組合持續改善gross-to-net。這樣有回答到嗎,Umer?
Joseph C. Papa - CEO & Chairman of the Board
Joseph C. Papa - CEO & Chairman of the Board
On the second part of your question, you asking us about the ongoing trial that we have in overt hepatic encephalopathy. A couple of things, I'll say. Number one, there are about 156,000 patients that are hospitalized because of hepatic encephalopathy. Obviously, anything we can do to reduce the hospitalization time or let's just say in the hospital as well as rehospitalization is an important question for us that we're looking at in that trial because we obviously think that's an important part of any pharmacoeconomic model and showing the value of our product. But importantly, there's a second reason for this trial. As you probably noted in the data that we're using our SSD formulation there. We expect that, that trial will give us some information on the use of SSD formulation and potential dose response, which can then help us with some of the later trials that we also believe are the larger opportunity. So it's important for our pharmacoeconomics to summarize and then also, it's important because it will give us a dose range and information that will help us as we look at some of the larger trials, for example, the prevention of the complication of decompensated cirrhosis as an example, with other indications and other things we're going to look at with either the XIFAXAN 550 or the SSD formulation. So important to us for the near-term pharmacoeconomic and also long term.
就你問題的第二部分,你是在問我們目前正在進行的顯性肝性腦病(overt hepatic encephalopathy)試驗。我會說幾點。第一,大約有156,000名患者因肝性腦病而住院。顯然,任何能縮短住院時間,或更廣義地說降低住院與再住院(rehospitalization)的措施,對我們而言都是重要課題;我們在該試驗中也正在評估,因為我們顯然認為這是任何藥物經濟學模型的重要部分,有助於展現我們產品的價值。但更重要的是,這項試驗還有第二個原因。如你可能已在我們使用的數據中注意到,我們在那裡採用的是SSD劑型。我們預期該試驗會提供一些關於SSD劑型使用方式與潛在劑量反應(dose response)的資訊,進而協助我們推進一些後續試驗,而我們也相信那些才是更大的機會。因此,總結來說,這對我們的藥物經濟學很重要;同時也很重要,因為它將提供劑量範圍與相關資訊,幫助我們在評估一些更大型試驗時做決策,例如以預防失代償性肝硬化併發症為例,還有其他適應症與其他我們將要研究的方向,無論是使用XIFAXAN 550或SSD劑型。所以,對我們的短期藥物經濟學與長期發展都很重要。
Operator
Operator
And our next question today comes from Dave Risinger of Morgan Stanley.
我們今天的下一個問題來自Morgan Stanley的Dave Risinger。
David Reed Risinger - MD in Equity Research and United States Pharmaceuticals Analyst
David Reed Risinger - MD in Equity Research and United States Pharmaceuticals Analyst
So I guess I wanted to start with LUMIFY. Could you just talk about that ramp? And I know that the TV ad was well received. Do you plan to run that more frequently in 2019 to drive greater adoption? Second question is, with respect to the February 25 Lotemax franchise line extension PDUFA, should we expect an on-time approval? Or could that potentially be delayed due to the FDA backlog as a result of the government shutdown this winter? And then finally, just on contact lenses, could you please talk about the potential timing for additional SiHy launches globally?
我想我先從LUMIFY開始。你能談談它的爬坡(ramp)情況嗎?我知道那支電視廣告反應很好。你們是否計畫在2019年更頻繁地投放,以推動更高的採用率?第二個問題,關於2月25日Lotemax系列產品線延伸(line extension)的PDUFA,你們是否預期能準時獲批?或者是否可能因為今年冬天政府關門導致FDA積壓而延遲?最後,關於隱形眼鏡,你能談談全球額外SiHy(矽水膠)新品上市的潛在時程嗎?
Joseph C. Papa - CEO & Chairman of the Board
Joseph C. Papa - CEO & Chairman of the Board
Sure. Let me start, on the LUMIFY, we are delighted what we're seeing. As we mentioned in the call that we're now up to approximately a 28% weekly share in the latest data that we've seen just -- since we've launched this product just in May, we're really excited about it. We are back with TV advertising, as you -- now as you speak. We think that's an important part of it, but we also think the other part of it is the integrated eye care approach we have allows our teams in ophthalmologist offices and optometry offices to drop off samples and that's the reason we are getting great referrals and why we're the #1 referral product for the treatment of redness relief from ophthalmologists and optometry. So we think it's the integrated approach that really is helping us with what we're doing in making LUMIFY a better product. And of course, the other important reason I must add is that we believe we've got a better mechanism of action. We do not constrict the arterial blood flow to the eye. We constrict the venous blood flow, which we think is a much better way of approach on the redness relief category. On the question, second question of Lotemax, the 0.38, you're absolutely correct. We have a late February date for the PDUFA. At this time, I really don't want to speculate as to where the FDA is in terms of approving this product. We're obviously putting together all the information, and we put together that information. We believe we know the FDA is making good progress on it, but I don't want to really speculate as to exact timing what the date is. The PDUFA date is the date, but obviously, we know that the FDA in the case of DUOBRII was not able to complete their PDUFA date filing review on time. So I'm not going to speculate on what's going to happen on the, I think, it's February 25 date. Final comment, contact lenses, as you noted, we did launch the silicone hydrogel in Japan, and we've got plans to roll that out globally. That global rollout will be predominantly -- for example, the U.S. will be sometime in 2020 in terms of our launch plans for the silicone hydrogel launch here in United States.
當然。我先從LUMIFY開始,我們對目前看到的表現非常滿意。如我們在電話會議中提到,根據我們看到的最新數據,自從我們在5月推出這個產品以來,目前每週市占率已約達28%,我們對此非常興奮。我們現在也已重新投放電視廣告,正如你所說。我們認為那是重要的一環,但我們也認為另一個關鍵在於我們的整合式眼科照護(integrated eye care)模式,使我們的團隊能在眼科醫師與驗光師診所提供試用裝,這也是我們獲得大量轉介、並成為眼科醫師與驗光師在「緩解眼紅」治療上轉介排名第一產品的原因。因此我們認為,正是這種整合式做法,真正幫助我們推動LUMIFY成為更好的產品。當然,我必須補充的另一個重要原因是,我們相信我們擁有更好的作用機轉(mechanism of action)。我們不會收縮眼部的動脈血流。我們收縮的是靜脈血流,我們認為這是在眼紅緩解品類中更好的處理方式。第二個問題關於Lotemax 0.38,你說得完全正確。我們的PDUFA日期在2月下旬。目前我真的不想推測FDA在核准這個產品方面進展到哪一步。我們當然正在彙整所有資訊,而且我們也已提交那些資訊。我們相信並且知道FDA正在取得良好進展,但我不想就確切時點或日期做推測。PDUFA日期就是那個日期,但顯然我們也知道,在DUOBRII的案例中,FDA未能在PDUFA日期前按時完成審查。所以我不會推測在我想是2月25日那個日期會發生什麼。最後談隱形眼鏡,如你所提到,我們已在日本推出矽水膠產品,並且計畫在全球推廣。該全球推廣的時程將以——例如美國市場——為主,依我們在美國的矽水膠上市規劃,時間大概會落在2020年某個時點。
Paul S. Herendeen - Executive VP & CFO
Paul S. Herendeen - Executive VP & CFO
I'm going to just finish up on that because I think the U.S. market, depending on the data set, uses approximately 40% of the global lens market, and so it's obviously a big target for us. The U.S. is also a market where more of the lenses are, I think, only -- I say only, only about 45% of the U.S. market is in daily lenses now, which is low relative to the rest of the world. So we want to be in daily lenses in a daily SiHy because that is a fast growing and expected to continue to be a fast-growing segment of the market.
我就把這點收個尾,因為我認為美國市場依不同的資料集而定,大約占全球隱形眼鏡市場的40%,所以顯然對我們而言是個很大的目標。美國同時也是一個市場,在那裡我認為更多的鏡片仍然是——我說「仍然」——目前美國市場只有大約45%是日拋鏡片,這相較於世界其他地區偏低。因此我們希望切入日拋鏡片、尤其是日拋矽水膠(SiHy),因為那是成長很快、且預期將持續快速成長的市場區隔。
Operator
Operator
Our next question comes from Chris Schott of JPMorgan.
我們的下一個問題來自摩根大通(JPMorgan)的Chris Schott。
Christopher Thomas Schott - Senior Analyst
Christopher Thomas Schott - Senior Analyst
Just 2 questions here. Maybe first on XIFAXAN and just elaborating a little bit more on the 2019 outlook. Do you see more growth and improvements this year or should we be thinking about 2019 more as a year where it's volume and gross price increases driving growth there? So I know in '18 that was a big component of growth, and I'm just trying to -- and then talking about the whole business, but XIFAXAN specifically in '19, will that be a component of growth? My second question was on organic delevering. You're allocating more capital to deals. You're also pivoting to offense a bit here. I guess, can you elaborate just how you're balancing acquisitions relative to the debt paydown in the story? I guess, in general, should we still think about most of your cash flow being allocated to debt paydown at this point with some smaller deals mixed in or could these transactions actually account for more meaningful piece of your cash flow on a go-forward basis?
這裡有兩個問題。第一個可能是關於XIFAXAN,想請你再多談一點2019年的展望。你們是否看到今年會有更多成長與改善,還是我們應該把2019視為主要由銷量與毛價上調來帶動成長的一年?我知道在2018年那是成長的一個很大組成,我只是想——然後再談到整體業務,但就XIFAXAN而言,2019年這會是成長的組成之一嗎?我的第二個問題是關於有機去槓桿。你們把更多資本配置到交易上。你們也在這裡稍微轉向進攻。我想請你們說明一下,你們如何在併購與償還債務之間取得平衡?更一般地說,我們是否仍應認為你們目前大部分的現金流會用於償債、同時穿插一些較小的交易,還是這些交易在未來其實可能占你們現金流更有意義的一部分?
Joseph C. Papa - CEO & Chairman of the Board
Joseph C. Papa - CEO & Chairman of the Board
Sure, good questions. I'll take the XIFAXAN question and then Paul will comment about the organic delevering. On the XIFAXAN, we're really excited by what we're seeing. If I just look at what's happening so far in the 2019 time frame, we're seeing somewhere in the -- for example, in the month of January, our XIFAXAN total prescriptions are up approximately 10%. So very strong growth in XIFAXAN volume. But we are projecting though as we think about is the combination in 2019 will be a combination of what we're seeing on prescription growth, call it high single digits there and then call it some net price improvements, which is a combination of gross price and also some gross to net things that we are doing. So I think, it's really a combination that we think can get XIFAXAN certainly to high single digit, low double digits in terms of the growth rate that we are projecting for XIFAXAN. So we're very excited. But one final comment I will say that some of you don't see, but we're also seeing very strong nonretail growth with XIFAXAN. That's the nonretail category, thinking of nursing homes, convalescent homes, hospital institutions, et cetera, where we're seeing actually they're also double-digit growth and that's another big driver, especially in the area of hepatic encephalopathy. So those have been the primary growth factors for XIFAXAN in 2019. Paul, do you want to take the question on the delevering in the debt?
好的,問題很好。我先回答XIFAXAN的問題,然後Paul會就有機去槓桿做評論。關於XIFAXAN,我們對目前看到的情況非常振奮。如果我只看2019年迄今的狀況,例如在1月份,我們XIFAXAN的總處方量約成長了10%。所以XIFAXAN的銷量成長非常強勁。不過我們在做2019年的預測時,認為將會是兩者的組合:一方面是我們看到的處方成長,我們稱之為高個位數;另一方面是一些淨價格改善,這是毛價以及我們正在進行的一些毛到淨(gross-to-net)措施的組合。因此我認為,這樣的組合可讓XIFAXAN達到我們所預測的成長率——當然可達高個位數、低雙位數。所以我們非常興奮。但我最後還想補充一點:有些人可能看不到的是,我們也看到XIFAXAN在非零售通路有非常強勁的成長。所謂非零售類別,是指療養院、護理之家、醫院機構等;我們看到那裡也有雙位數成長,而這也是一個重要的驅動因素,特別是在肝性腦病變(hepatic encephalopathy)領域。所以這些是2019年XIFAXAN的主要成長因素。Paul,你要回答關於去槓桿與債務的問題嗎?
Paul S. Herendeen - Executive VP & CFO
Paul S. Herendeen - Executive VP & CFO
I do, but I want to chime in on the gross net on XIFAXAN because there's -- as a financial analyst and I know each one on the phones is a financial analyst, it's important. I mean, remember that back in -- when we reported our Q1, we talked about a pretty substantial improvement in gross to net from better pricing in that nonretail channel Joe just referenced, which is growing quite nicely. We're going to lap that. So that had been kind of a step function, it had been a nice tailwind for us in Q1, Q2, Q3, Q4, for the full year. We're going to lap that, and it's a good thing. I mean, it's all good, but I think, looking ahead to 2019 v. '18, Joe said exactly right. It's like we expect something on a unit basis and high single digits and price. Whatever gross selling price increase we take, we don't obviously expect to net that and realize all of that, but the 2 drivers next year will be -- next year versus '18 will be volume and whatever we can net out of price increases that we take. With respect to the question around how do we expect to deploy our cash flow, Joe finished up with a slide that said, we have $1 billion to be used for debt and/or bolt-on acquisitions. I mean, this is -- our priority is to reduce that debt. Now that said, it's not a priority where you say when you have a great opportunity that we think is value generative and helpful to all stakeholders. We're going to pursue that, and I think the best example of that is the ongoing situation with Synergy, where as Joe reported in his remarks, we put in a shocking (sic) [stalking] horse bid. It's $200 million. It's $200 million. If we were successful at that level, I'm not suggesting that's how that will sort out, but if we're successful at that level that $1 billion, $200 million of it would definitely be allocated to business development, and there are other, smaller items that throughout the year, we would expect to pursue to continue to add to our R&D portfolios or to our marketed portfolios for each one of our core and important business. So it's a very difficult question because in the absence of something value generative, we're going to reduce our debt. That's super clear. But if there are these opportunities that we shift and deploy them against business development, and it makes sense, we're going to do that and in my opinion like, for example, the Synergy thing, that is something that makes an incredible amount of sense based on the strategic fit within our Salix portfolio. So that we will allocate capital to -- for BD and other small things. I don't know if I answer you. I can't answer your question specifically, but I hope I provided at least the way we're thinking about it.
我要,但我想先就XIFAXAN的毛到淨補充一下,因為——作為一名財務分析師,而且我知道電話上的每一位都是財務分析師——這點很重要。我的意思是,記得在——當我們公布第一季(Q1)時,我們談到毛到淨有相當顯著的改善,來自Joe剛提到、成長相當不錯的非零售通路中更好的定價。我們將會進入同基期比較(lap that)。所以那有點像是一個階梯式的提升,對我們在Q1、Q2、Q3、Q4乃至全年都是一個不錯的順風。我們會進入同基期比較,而這是件好事。我的意思是,一切都很好,但我認為展望2019相對於2018,Joe說得完全正確。就像我們預期在單位數量上會有一些表現、在高個位數,並且還有價格。無論我們採取多少毛銷售價格的調升,我們顯然不預期能在淨額上完全反映並實現全部;但明年——也就是明年相對於2018——兩個驅動因素將是銷量,以及我們能從所採取的價格上調中淨化(net out)出來的部分。至於你問到我們預期如何運用現金流,Joe最後用一張投影片說明,我們有10億美元可用於償債和/或補強型(bolt-on)併購。我的意思是——我們的優先事項是降低債務。不過話說回來,這並不是那種你會說「即使遇到我們認為能創造價值、並對所有利害關係人有幫助的絕佳機會也不做」的優先事項。我們會去追求那樣的機會,我認為最好的例子就是目前與Synergy相關的進展;正如Joe在他的發言中報告的,我們提出了一個令人震驚的(原文如此)[stalking] horse bid(領頭馬投標)。金額是2億美元。是2億美元。如果我們能以那個水準成功——我不是在暗示最後會如何定案——但如果我們以那個水準成功,那10億美元中就會有2億美元明確配置到業務開發(BD);此外,全年我們也預期會追求其他較小的項目,以持續擴充我們的研發(R&D)產品組合,或我們已上市的產品組合,涵蓋我們每一個核心且重要的業務。所以這是一個非常困難的問題,因為在沒有能創造價值的事項時,我們就會降低債務。這點非常清楚。但如果出現這些機會,而我們把資源轉向並配置到業務開發上且合理可行,我們就會這麼做;以我看來,例如Synergy這件事,基於它與我們Salix產品組合的策略契合度,這是非常有道理的。因此我們會配置資本用於——用於BD以及其他小型事項。我不知道我是否回答到你的問題。我無法具體回答你的問題,但我希望至少提供了我們的思考方式。
Operator
Operator
The next question comes from Irina Koffler of Mizuho.
下一個問題來自瑞穗(Mizuho)的 Irina Koffler。
Irina Rivkind Koffler - MD of Americas Research & Senior Analyst
Irina Rivkind Koffler - MD of Americas Research & Senior Analyst
I just wanted to verify that your guidance for next year, does it include any benefit from TRULANCE or any sales force expansion to Salix?
我只是想確認一下,你們對明年的指引是否包含來自 TRULANCE 的任何效益,或是對 Salix 的任何銷售團隊擴編?
Joseph C. Papa - CEO & Chairman of the Board
Joseph C. Papa - CEO & Chairman of the Board
The guidance that we give does not include any M&A, to be clear. It does include our plans for XIFAXAN, but not specifically related to what we are planning for incremental sales reps or anything along those lines if we are successful in acquiring TRULANCE. Is that clear?
我們所提供的指引不包含任何併購(M&A),先說清楚。它包含我們對 XIFAXAN 的規劃,但並非特別針對若我們成功收購 TRULANCE,將新增銷售代表或任何類似事項的規劃。這樣清楚嗎?
Irina Rivkind Koffler - MD of Americas Research & Senior Analyst
Irina Rivkind Koffler - MD of Americas Research & Senior Analyst
Yes, and then just one follow-up. You're obviously doing very well in Solta and cosmetic dermatology. Is there any thought to expanding your presence in that segment?
是的,然後再追問一個問題。你們在 Solta 與醫學美容皮膚科顯然做得非常好。是否有考慮擴大你們在該細分領域的布局?
Joseph C. Papa - CEO & Chairman of the Board
Joseph C. Papa - CEO & Chairman of the Board
Yes, Paul made a comment that we have a leader there, Tom Hart, who's doing an absolute phenomenal job in turning around that business, and what we are -- what he's doing is he's really focused on a couple of things. Number one, launching some new products. He's got a new Thermage product that he's launching, and it's doing very well with that product launch. Number two, he is looking at what I would refer to as geographic expansion. He is looking at places where we have an opportunity to do better than existing business, so we do very well in the United States. We do very well in Asia, but we have a significant opportunity in Europe as an example. So Tom is putting some incremental resources to work there to up -- look at what we think is a good opportunity for growth in the European and some of the other areas of the world that we just are not as well represented. So we do think there's some opportunities, a lot of upsides to be clear based on what we think is really strong leadership by Tom Hart and the team.
是的,Paul 提到我們那邊有一位領導者 Tom Hart,他在扭轉那項業務方面做得非常出色;而我們——他正在做的事情其實聚焦在幾個面向。第一,推出一些新產品。他正在推出一款新的 Thermage 產品,而這次產品上市表現非常好。第二,他在看我所稱的地理擴張。他在尋找我們有機會做得比現有業務更好的地區;例如我們在美國做得很好。我們在亞洲也做得很好,但以歐洲為例,我們有很大的機會。因此 Tom 正在投入一些額外資源,在那裡推進——著眼於我們認為在歐洲以及世界其他一些我們布局較弱的地區,存在良好的成長機會。所以我們確實認為有一些機會;坦白說,上行空間很大,這是基於我們認為 Tom Hart 與團隊非常強的領導力。
Paul S. Herendeen - Executive VP & CFO
Paul S. Herendeen - Executive VP & CFO
Yes, I want to -- it's Paul. I want to follow on, on that as well is I think, the best way to build value is to optimize what you own and what you have in your own internal pipeline. And I daresay before Tom joined us and he was brought to us by Tom Appio, who runs our international business, which was a great thing for us, we had not optimized our existing portfolio nor were we positioned to optimize the new products that we already had the ability to roll out on our own and drive organic growth. That's why i.e. Joe, you can hear his enthusiasm about this business and certainly mine as well. We've called it out a handful of quarter -- quarters in a row here. We have an interesting portfolio. If there are opportunities to add to that, we surely would. But we have a lot of opportunity within that existing portfolio plus new products that we're rolling out from our pipeline. So well positioned in Global Solta.
是的,我想——我是 Paul。我也想延續剛才那點,我認為建立價值的最佳方式,是把你所擁有的資產以及內部產品管線做最佳化。我敢說,在 Tom 加入我們之前——他是由負責我們國際業務的 Tom Appio 引薦給我們的,這對我們來說非常好——我們既沒有把既有產品組合最佳化,也沒有準備好去最佳化那些我們其實已經有能力自行推出、並推動有機成長的新產品。這就是為什麼,也就是說。Joe,你可以聽到他對這項業務的熱情,我當然也是。我們已經連續好幾個季度把它特別點出來。我們有一個很有意思的產品組合。如果有機會在此基礎上再增加一些資產,我們當然會。但我們在既有產品組合內,以及從我們管線推出的新產品方面,都有很多機會。因此在全球 Solta 的布局上,我們處於很好的位置。
Operator
Operator
Our next question comes from David Amsellem of Piper Jaffray.
我們的下一個問題來自 Piper Jaffray 的 David Amsellem。
David A. Amsellem - MD and Senior Research Analyst
David A. Amsellem - MD and Senior Research Analyst
So just have a couple. So just coming back to M&A. I may have missed this, but maybe you can put a number on deal capacity or what you're wherewithal is in terms of deal size or aggregate transaction size and how much is earmarked for transactions. That's number one. And then number two, just talking about the cash pay dermatology model, can you just talk about the mechanics here? I mean, is this going to be products primarily dispensed in the physicians office, like what the Obagi model was, and how many medical derm products do you envision falling under this model? And then lastly, on the rifaximin studies, you highlighted 4. Maybe give us some color on timing for data readouts on those studies.
我有幾個問題。先回到併購(M&A)。我可能漏聽了,但你們是否可以量化一下交易承載能力,或就交易規模/累計交易規模而言你們的能力範圍,以及有多少資金是預留給交易的。這是第一點。第二,談到自費(cash pay)的皮膚科模式,你們能否說明一下這裡的運作機制?我的意思是,這會不會主要是像 Obagi 模式那樣,以在醫師診所內配發(dispensed)的產品為主?你們預期有多少醫學皮膚科產品會納入這個模式?最後,關於 rifaximin 的研究,你們提到了 4 項。能否補充一下這些研究的數據讀出(data readout)時程?
Joseph C. Papa - CEO & Chairman of the Board
Joseph C. Papa - CEO & Chairman of the Board
Paul, why don't you take the first one? And I'll take cash pay and rifaximin.
Paul,你先回答第一個好嗎?我來回答自費模式和 rifaximin。
Paul S. Herendeen - Executive VP & CFO
Paul S. Herendeen - Executive VP & CFO
Yes, sure, I mean -- David, thanks for the question. It's hard to put a number on what we might be willing to doing in M&A. We obviously have a limited capacity because of the level of our debt and limitations of our ability to generate free cash flow, which we can choose to either use to reduce debt or to deploy against value-generative BD opportunities. I daresay, if we do Synergy this year, it's going to be the -- that takes a good amount of our capacity out for 2019. If we're so fortunate as to be able to conclude that deal, it is one of the challenges that we face as we are a company that carries a lot of debt. We are highly levered and so we need to be incredibly judicious in the deployment of capital for BD, and it's just -- we don't have a big checkbook. We just don't, and that's the way it is until we can change it. And I'm not sure I answered your question, but I can't give you and say, "Oh, it's 40% of" whatever. It's not. It's based on our ability to balance between the absolute requirement that we continue to prioritize using cash to reduce debt and not -- and being willing to place strategic bets on situations that we think are really going to be good for us in the long term.
好的,當然——David,謝謝你的問題。很難為我們在併購(M&A)上可能願意做的事情給出一個數字。由於我們的負債水準,以及我們產生自由現金流的能力所受的限制,我們的承載能力顯然有限;而這些自由現金流我們可以選擇用來降低負債,或用於能創造價值的商務開發(BD)機會。我敢說,如果我們今年完成 Synergy,那——這會在 2019 年占用我們相當一部分的承載能力。如果我們有幸能夠完成那筆交易,這也是我們面臨的挑戰之一,因為我們是一家背負大量負債的公司。我們槓桿很高,因此在將資本用於 BD 時必須極其審慎;而且就是——我們沒有一本很大的支票簿。我們確實沒有;在我們能改變之前,現況就是如此。我不確定我是否回答了你的問題,但我無法告訴你並說:「哦,是 40% 的」之類的。不是那樣。這取決於我們在兩者之間取得平衡的能力:一方面是我們必須持續優先使用現金來降低負債的絕對要求;另一方面是在我們認為長期對我們非常有利的情境下,願意下策略性賭注。
Joseph C. Papa - CEO & Chairman of the Board
Joseph C. Papa - CEO & Chairman of the Board
David, on the second part of your questions about the cash pay model and dermatology. What we are trying to solve here is what the problems are in the dermatology space and some of these products, especially in areas like acne, for example, there is an uncertain environment with prior authorizations. There is uncertainty there for both the physician and the patient. There is expensive co-pays often in that category, and there is variable formulations from the generic companies, especially in the topical products. What we are going to seek to do is to bring forward a brand formulation that we believe will have predictable access, in other words, your patients will know, physicians will know how to get it, either through the physician's office, through retail stores or through a mail-order facility. So predictable access, and it will have known pricing, very predictable price. In other words, we'll be able to give our belief that we can make this product available at a set price. So that's what we think will be very helpful to a large number of patients and physicians because the market will become very predictable versus what -- unfortunately, we see today is a very unpredictable market. So Bill Humphries, our leader in this derm business, is moving forward with this. We have a lot more to say about specific products but think about some of the older products that we have in the areas of acne, also in some of the topical dermatitis and other areas that will be coming forth with our products. So a lot more to say about this as we roll it out, but we think it's a good way to look at it. On the third part of your first question was rifaximin. You can hear our excitement that we're doing 2 things. Number one, coming out with the new formulations, and then number two, coming out with the new indications. So I don't know I can go through all of the specifics on the call now because there is a lot that's going to go on there, but I'll try to hit the highlights. In the post-operative Crohn's disease, it's a Phase III trial. It's using the EIR product that we are partnering with Alfasigma. I remind you that we had an arbitration with Alfasigma, and we found a solution to that. We resolved that. Good work by our business development and legal team, and we'll be headed into that Phase III trial with the post-operative Crohn's, and our expectation is we'll have data on that sometime in the, let's call it the 20 -- data sometime in the '20, '21, '22 time frame depending on what happens there. On the second area that we're looking at is the OHE study. That's the acute study I mentioned previously on the call. That's really, as I said, it's trying to look at the pharmacoeconomics of XIFAXAN, but importantly, giving us some information on SSD that we can then leverage and take into additional clinical trials. That will hit some data later this year, but I probably don't want to give specifics about filing or anything along those lines because that's something that we're still assessing over the long term. On the other area of SIBO, that as we mentioned is in a Phase II. There's a lot of patients with SIBO. We're looking at 17 million patients in the United States. As I mentioned before, we see somewhere approximately 12 million patients who are treating IBS-D. So it's somewhat of a subset of the SIBO population. So large numbers there. I don't have a specific date that I will share right now, but call it -- certainly, it will take a couple of years to get the data on that. And then we'll make decisions on where we're going to go in there, but think, certainly, in that '20, '21, '22 time frame for data and then where we want to be thinking about it for the future. So I think, I've tried to answer all the questions there relative to your question on rifaximin study. But we're very optimistic, and we are going to invest behind our rifaximin franchise.
David,關於你問題的第二部分,涉及現金自付(cash pay)模式與皮膚科。我們在此試圖解決的是皮膚科領域以及其中一些產品所面臨的問題;尤其是在例如痤瘡等領域,事前授權(prior authorizations)的環境充滿不確定性。這對醫師與病患而言都存在不確定性。該類別往往有昂貴的自付額(co-pays),而且學名藥公司在配方上存在差異,特別是在外用產品方面。我們打算推進的是一個品牌配方(brand formulation),我們相信它將具備可預期的取得途徑;換言之,你的病患會知道、醫師也會知道如何取得它——無論是透過醫師診所、零售通路或郵購(mail-order)機構。因此是可預期的取得性,且會有明確定價、非常可預期的價格。換言之,我們相信能以固定價格提供這項產品。因此我們認為,這將對大量病患與醫師非常有幫助,因為市場將變得非常可預期;相較之下——不幸的是——我們今天看到的是一個非常不可預期的市場。因此,我們皮膚科業務的負責人Bill Humphries正在推動此事。我們對特定產品還有很多可以說,但可以想想我們在痤瘡領域的一些較舊產品,以及一些外用皮膚炎(topical dermatitis)與其他領域;這些都將隨著我們的產品陸續推出。因此,隨著我們逐步推出,我們還會有更多要說的,但我們認為這是一個很好的切入方式。你第一個問題的第三部分是rifaximin。你可以感受到我們的興奮,因為我們正在做兩件事。第一,推出新的配方;第二,推出新的適應症。我不確定我現在是否能在電話會議上把所有細節都講完,因為那裡會有很多事情要進行,但我會試著抓重點。在術後克隆氏症(post-operative Crohn's disease)方面,這是一項第三期(Phase III)試驗。它使用的是我們與Alfasigma合作的EIR產品。我提醒各位,我們曾與Alfasigma進行仲裁,而我們已找到解決方案。我們已經解決了。我們的業務開發與法務團隊做得很好;我們將推進術後克隆氏症的第三期試驗,我們預期會在某個時間點取得數據,姑且稱之為在20——也就是在'20、'21、'22這段期間內的某個時點取得數據,取決於進展情況。我們正在看的第二個領域是OHE研究。那是我先前在電話會議中提到的急性研究(acute study)。如我所說,它真正要看的,是XIFAXAN的藥物經濟學(pharmacoeconomics);但更重要的是,提供我們關於SSD的一些資訊,之後我們可以加以運用並帶入更多臨床試驗。該研究會在今年稍晚產出一些數據,但我可能不想就申報(filing)或任何類似事項給出具體說法,因為那是我們仍在長期評估的事情。另外一個SIBO領域,如我們提到的,目前在第二期(Phase II)。SIBO病患很多。我們估計美國有1,700萬名病患。如我先前提到,我們看到大約有1,200萬名病患正在治療IBS-D。因此它在某種程度上是SIBO族群的一個子集合。所以數量相當龐大。我目前沒有要分享的具體日期,但可以說——要取得那方面的數據,肯定需要幾年時間。接著我們會決定要如何推進,但可以預期,數據大概會落在'20、'21、'22這段期間,然後再思考未來要如何布局。所以我想,我已經就你關於rifaximin研究的問題,盡量回答了所有相關問題。但我們非常樂觀,而且我們將加大投資,支持我們的rifaximin產品線(franchise)。
Operator
Operator
And our next question today comes from David Steinberg of Jefferies.
我們今天的下一個提問來自Jefferies的David Steinberg。
David Michael Steinberg - Equity Analyst
David Michael Steinberg - Equity Analyst
I have a few questions on your GI business. So first, back to XIFAXAN. Your unit growth has been steadily improving, I think, up to 8% according to IMS. You've recently had some positive data in pain associated with IBS-D and Joe, you mentioned that about 90% of the market is untapped. So just curious, now that you've settled with Teva and you have a runway for 5, 6, 7 years, what sort of unit growth -- given these dynamics, what sort of unit growth you think you can put up in the near to medium term for XIFAXAN given it's your biggest drug? And then secondly, on Synergy, what sort of sales -- it's a good strategic fit, but what sort of sales would you need to achieve assuming you get it to start turning a profit, and what sort of PK sales expectations would you have for TRULANCE? And then finally, Cosmo has now been approved for rifaximin in the case for traveler's diarrhea. From what you can see in the market, are they taking share and what's your view on any off-label prescriptions for indications like IBS-D and HA?
我對你們的腸胃(GI)業務有幾個問題。首先,回到XIFAXAN。你們的單位銷量(unit)成長一直在穩步改善,我認為根據IMS已提升到8%。你們最近在與IBS-D相關的疼痛方面取得了一些正面數據,而且Joe,你提到大約90%的市場尚未被開發。所以我想請教,既然你們已與Teva達成和解,並且有5、6、7年的時間跑道,在這些動態之下,考量XIFAXAN是你們最大的藥物,你們認為在短中期內XIFAXAN的單位銷量成長大概可以做到什麼程度?第二,關於Synergy,這是一個很好的策略契合,但假設你們能讓它開始轉虧為盈,你們需要達到什麼樣的銷售水準?以及你們對TRULANCE的處方量(PK)銷售預期會是什麼?最後,Cosmo現在已獲准rifaximin用於旅遊者腹瀉(traveler's diarrhea)。就你們在市場上所見,他們是否正在搶占市占?以及你們如何看待像IBS-D與HA等適應症的任何超適應症處方(off-label prescriptions)?
Joseph C. Papa - CEO & Chairman of the Board
Joseph C. Papa - CEO & Chairman of the Board
Sure. I think you got a lot of questions in there, David, but I'll try to -- if I don't catch them all, let me -- remind me. On the first one, though, we're very excited what we're seeing with XIFAXAN. The only thing I'm going to comment on is at least during the month of January, we actually saw about 10% growth in our year-over-year growth with XIFAXAN, so very strong unit in growth and as I mentioned in the nonretail segment, we're seeing even higher growth. So very excited about it, but just in terms of what we're expecting over the long term, I think it was really the nature of your question. I think if you think about volume growth in XIFAXAN, somewhere in that like, call it high single digit, that's probably what I would stick with, not going into that double-digit side. Obviously, if we can get some additional net pricing, it might help grow -- show even more but high single digits is the unit volume growth I would probably think about as you're modeling. On the question of Synergy, I think, I said in the call, we're really excited about it. We think there's a great opportunity there with Synergy, especially given the fact that we bring some important experience we have experienced in the gastroenterologist office, which we think is helpful to what we need to do with Synergy. Number two is we've got a great supply chain capability. Dennis Asharin and the team with you are doing really well on the supply chain and then we've got some problems we have to fix with Synergy. So that is what we think is an important competitive advantage that we bring to this situation. And then finally, one of the areas that we were concerned about as we were watching externally was the market access side for Synergy. We think we also have new leadership in our market access team and a good market access team that can help us to get the appropriate opportunity for the future, assuming we can get Synergy at the right price. Final comment, question I think you asked was in terms of what's happening with Cosmo. I can say that our sales force has not seen any activity or sales presence in the gastroenterologist or primary care offices from Cosmo. We can say with conviction, we know there are some significant barriers for entry in the GI offices, and we're very pleased with our position for rifaximin and specifically, XIFAXAN as we sit here today, but we have not seen anything from Cosmo at this time, in the marketplace. I think I got all your questions, David.
好的。David,我想你在裡面問了很多問題,但我會盡量——如果我沒有全部涵蓋到,請你——提醒我。先談第一個,我們對於目前在 XIFAXAN 上看到的表現感到非常振奮。我唯一要評論的是,至少在一月份這個月,我們實際上看到 XIFAXAN 的年對年成長約 10%,因此單位量成長非常強勁;而且如我在非零售通路所提到的,我們看到的成長甚至更高。所以我們非常興奮;但就我們對長期的預期而言,我想那才是你問題的本質。我認為如果你在思考 XIFAXAN 的量成長,大概會落在所謂的高個位數百分比,我大概會維持這個看法,而不會走到雙位數。當然,如果我們能取得一些額外的淨價格提升,可能會有助於成長——呈現得更高;但就你在建模時,我會把單位量成長視為高個位數。關於 Synergy 的問題,我想我在電話會議中說過,我們對此非常興奮。我們認為 Synergy 有很好的機會,特別是考量到我們在腸胃科醫師診所端累積了一些重要經驗,我們認為這對於我們需要在 Synergy 上做的事情很有幫助。第二,我們具備很強的供應鏈能力。Dennis Asharin 以及你們那邊的團隊在供應鏈方面做得非常好,而 Synergy 也確實有一些問題需要我們去修正。因此,我們認為這就是我們在此情境下帶來的一項重要競爭優勢。最後,我們在外部觀察時曾經擔心的一個領域,是 Synergy 的市場准入(market access)面向。我們認為我們的市場准入團隊也有新的領導層,而且是一支很好的市場准入團隊,能協助我們在未來取得適當的機會——前提是我們能以合適的價格拿下 Synergy。最後一個評論/問題,我想你問的是 Cosmo 的情況。我可以說,我們的業務團隊在腸胃科或基層醫療診所,沒有看到 Cosmo 有任何活動或銷售佈局。我們可以很有把握地說,我們知道在 GI 診所端存在一些顯著的進入障礙;而且就利福昔明(rifaximin),特別是 XIFAXAN 而言,我們對目前的市場地位非常滿意;但截至目前,我們在市場上沒有看到 Cosmo 的任何動作。David,我想我把你的問題都回答到了。
Operator
Operator
Today's final question comes from Louise Chen of Cantor.
今天最後一個問題來自 Cantor 的 Louise Chen。
Louise Alesandra Chen - Senior Research Analyst & MD
Louise Alesandra Chen - Senior Research Analyst & MD
So I have 2 questions. First question I had was you've said that your Significant Seven products are expected to double again in 2019. Just curious which products are driving that? And are there any, in particular, that you're very excited about? And then secondly, are you still considering options to meaningfully delever your balance sheet? And if so, what are some of those key options that you're considering?
我有兩個問題。第一個問題是,你們曾表示「重要七大(Significant Seven)」產品預期在 2019 年將再次翻倍。我想了解是哪些產品在推動這個成長?以及是否有任何特別讓你們感到非常興奮的產品?第二,你們是否仍在考慮能夠實質降低資產負債表槓桿的選項?如果是的話,你們正在考慮的關鍵選項有哪些?
Joseph C. Papa - CEO & Chairman of the Board
Joseph C. Papa - CEO & Chairman of the Board
Sure. I'll take that first part and then Paul, you want to take the comment on the second part of delevering. On the Significant Seven, I think, probably the best way to say it is that we like all the 7. We think all 7 of them are really the opportunity for growth, and we put them together specifically because as we talked about going back to 2017, they were under, call it, $75 million of revenue, and we thought about what was going to drive the growth of our business, and we said, these 7 products are going to be key to us. Clearly, there's a big, big opportunity in dermatology as we bring SILIQ to the market, we get BRYHALI approved and upon the approval of DUOBRII, we think those 3 products are going to be an important driver not only of our Significant Seven but also the turnaround in dermatology. So I'd have to say that those are clearly important drivers to our future success with our dermatology turnaround. But we do think just to summarize my comment, all 7 products are important to us for the point of view of both the growth aspects, but also how we'll turn around the overall dermatology business. Paul, do you want to take the second part of Louise's question?
好的。我先回答第一部分,然後 Paul,你要不要回應第二部分關於去槓桿的問題。關於「重要七大」,我想最好的說法大概是:我們喜歡這 7 個產品。我們認為這 7 個都是真正的成長機會;我們之所以把它們放在一起,是因為如同我們回到 2017 年所談到的,當時它們的營收都低於——大概——7,500 萬美元,我們在思考什麼會驅動公司業務成長時,我們認為這 7 個產品對我們會是關鍵。很明顯,當我們把 SILIQ 推向市場、讓 BRYHALI 獲得核准,以及在 DUOBRII 獲准之後,我們認為這三個產品在皮膚科領域有非常、非常大的機會;它們不僅會成為「重要七大」的重要驅動力,也會推動皮膚科業務的翻轉。所以我必須說,這些顯然是我們未來成功、以及皮膚科翻轉的重要驅動因素。但我也認為,總結我的評論,從成長面向來看,這 7 個產品對我們都很重要;同時,它們也關係到我們如何扭轉整體皮膚科業務。Paul,你要不要回答 Louise 第二部分的問題?
Paul S. Herendeen - Executive VP & CFO
Paul S. Herendeen - Executive VP & CFO
Yes, sure. I mean, obviously, the best way is for us to delever on or grow our adjusted EBITDA. Secondarily, to prioritize use of cash flow to continue to reduce that debt. And last on that list would be to consider potential equity or equity-linked securities. I'd say that we have made an enormous amount of progress in managing our cap structure, particularly the liability side of our cap structure over the last couple of years. Great leadership from Will Woodfield, our treasurer. It's -- right now, we're okay with where we are leverage wise, and if we look at our forecast over the next few years, we will generate enough cash to help us significantly advance the ball in reducing our leverage in addition of the obvious benefits of growing our adjusted EBITDA. So we feel pretty good about where we are right now and not compelled to do anything. We'll just continue to look at for managing the cap structure side at opportunities to continue to target those debt stacks that come due. I mean, even though we made such great progress I'll -- looking out to 2023, where there's a hefty amount of almost circa $6 billion of unsecured debt that comes due out there that we want to start looking at and thinking about taking that out. But in terms of steps that -- it's stay the course, let's grow our EBITDA, let's prioritize use of our cash to reduce debt, and we'll see how it goes.
是的,當然。我的意思是,很明顯,對我們而言去槓桿的最佳方式,是降低槓桿比率或提升我們的調整後 EBITDA。其次,是優先運用現金流持續降低債務。而在那份清單的最後,才會考慮潛在的股權或股權連結型證券。我想我們在管理資本結構方面,特別是資本結構中的負債端,在過去幾年已經取得了巨大的進展。這要歸功於我們財務主管(treasurer)Will Woodfield 的出色領導。就目前而言,我們對目前的槓桿水準是可以接受的;而且如果看我們未來幾年的預測,我們將產生足夠的現金,除了調整後 EBITDA 成長帶來的明顯效益之外,也能幫助我們在降低槓桿方面大幅向前推進。因此,我們對目前的狀況感覺相當不錯,也不覺得被迫一定要做什麼。我們會持續在資本結構管理面向,尋找機會,繼續鎖定那些即將到期的債務梯次(debt stacks)。我的意思是,儘管我們已經取得很大進展,但往 2023 年看,屆時會有一筆相當可觀、接近約 60 億美元的無擔保債務到期,我們希望開始著手觀察並思考如何處理、把它替換掉。但就步驟而言——就是維持既定方向:讓 EBITDA 成長、優先用現金降低債務,然後再看後續發展。
Joseph C. Papa - CEO & Chairman of the Board
Joseph C. Papa - CEO & Chairman of the Board
Thank you, everyone, for joining us today, and look forward to having a chance to catch up with everyone over the next weeks ahead of us. Thank you. Have a great day, everyone.
感謝各位今天加入我們,也期待在接下來幾週有機會與各位再進一步交流。謝謝。祝各位有美好的一天。
Operator
Operator
And thank you, sir. Today's conference has now concluded. And we thank you all for attending today's presentation. You may now disconnect your lines, and have a wonderful day.
也謝謝您,先生。今天的電話會議到此結束。感謝各位參加今天的簡報。各位現在可以掛線,祝各位有美好的一天。